Abstract
Refractory ascites is a complication of decompensated liver cirrhosis and is an indicator of poor prognosis. Portal hypertension and renal sodium retention are involved in the occurrence of refractory ascites. The diagnosis of refractory ascites is based on the criteria advocated by the International Ascites Club (IAC). Exclusion of the conditions that induce transient refractoriness to diuretics is important in the differential diagnosis. In Japan, tolvaptan, an oral arginine vasopressin V2 receptor antagonist, has been used as a new diuretic for ascites in combination with conventional diuretics since the drug was approved in 2013. As the relation between renal dysfunction and poor prognosis has become evident, preservation of renal function should be considered while selecting therapeutic options. An appropriate combination of diuretic therapy using tolvaptan and conventional diuretics may offer the possibility to control ascites without deterioration of renal function. Further investigation to clarify the role of the novel diuretic drug, tolvaptan, in the treatment of cirrhotic refractory ascites is necessary.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 188 studies. J Hepatol. 2006;44(1):217–31.
Gine’s P, C’ardenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med. 2004;350:1646–54.
Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62(1):131–7.
Angeli P, Gin’s P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968–74.
Salerno F, Guevara M, Bernardi M, et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010;30(7):937–47.
Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014;18(2):281–91.
Hou W, Sanyal AJ. Ascites: diagnosis and management. Med Clin North Am. 2009;93(4):801–17.
Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol. 2001;34(1):32–7.
Singhal S, Baikati KK, Jabbour II, et al. Management of refractory ascites. Am J Ther. 2012;19(2):121–32.
Runyon BA, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis: update 2012. http://www.aasld.org/publications/practice-guidelines-0.
Pirlich M, Selberg O, Böker K, et al. The creatinine approach to estimate skeletal muscle mass in patients with cirrhosis. Hepatology. 1996;24(6):1422–7.
Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23:164–76.
Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38(1):258–66.
Fukui H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 2016;51(7):629–50.
Wong F, Watson H, Gerbes A, et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut. 2012;61(1):108–16.
Sakaida I, Kawazoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44(1):73–82.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Segawa, M., Sakaida, I. (2019). Diagnosis of Refractory Ascites. In: Obara, K. (eds) Clinical Investigation of Portal Hypertension. Springer, Singapore. https://doi.org/10.1007/978-981-10-7425-7_50
Download citation
DOI: https://doi.org/10.1007/978-981-10-7425-7_50
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-7424-0
Online ISBN: 978-981-10-7425-7
eBook Packages: MedicineMedicine (R0)